Regencell Bioscience (NASDAQ:RGC) Stock Falls 6.8% – What’s Next?

Regencell Bioscience Holdings Limited (NASDAQ:RGC)’s stock price traded down 6.8% on Monday. The company traded as low as $7.13 and last traded at $6.8510. Approximately 23,588 shares changed hands during trading, a decline of 92% from the average session volume of 281,447 shares. The stock had previously closed at $7.35.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on RGC shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Regencell Bioscience in a research note on Monday, September 21st. Wall Street Zen downgraded Regencell Bioscience from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. One analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

Regencell Bioscience Stock Up 14.9%

The business has a fifty day moving average price of $6.04 and a 200 day moving average price of $14.43.

Regencell Bioscience (NASDAQ:RGC) last issued its earnings results on Wednesday, October 7th. The company reported ($0.01) earnings per share (EPS) for the quarter.

Institutional Trading of Regencell Bioscience

Large investors have recently added to or reduced their stakes in the stock. Seven Fleet Capital Management LP purchased a new position in Regencell Bioscience in the fourth quarter valued at about $92,000. Amundi acquired a new position in shares of Regencell Bioscience during the first quarter worth about $219,000. Finally, Bank of America Corp DE boosted its position in shares of Regencell Bioscience by 59,113.8% in the first quarter. Bank of America Corp DE now owns 17,172 shares of the company’s stock worth $437,000 after buying an additional 17,143 shares during the period. 0.13% of the stock is currently owned by institutional investors and hedge funds.

Regencell Bioscience Company Profile

Regencell Bioscience Holdings Limited is a clinical-stage biotechnology company focused on developing traditional Chinese medicine (TCM) treatments for neurocognitive disorders and degenerative conditions. Its research has centered primarily on conditions such as dementia and attention-deficit/hyperactivity disorder (ADHD), with the goal of developing herbal formulations that may address underlying symptoms and disease-related challenges.

The company’s product development programs include proprietary TCM formulations intended for neurological and cognitive conditions.